ABCL
EquityAbCellera Biologics Inc.
Health Care · Biotechnology
$3.71
+3.71 (+0.00%)
Open
N/A
Day Range
$3.60 - $3.76
52W Range
$1.89 - $6.52
Volume
3M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $120.24 | N/A | 0.83% | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.27 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.95 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.67 | N/A | 2.83% | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.57 | N/A | - | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.66 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $23.06 | N/A | - | +0.00% |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ABCL
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ABCL.